DNA-pools targeted-sequencing as a robust cost-effective method to detect rare variants: Application to dilated cardiomyopathy genetic diagnosis
Clin Genet. 2023 Oct 30. doi: 10.1111/cge.14427. Online ahead of print.ABSTRACTDilated cardiomyopathy (DCM) is a heart disease characterized by left ventricular dilatation and systolic dysfunction. In 30% of cases, pathogenic variants, essentially private to each patient, are identified in at least one of almost 50 reported genes. Thus, while costly, exons capture-based Next Generation Sequencing (NGS) of a targeted gene panel appears as the best strategy to genetically diagnose DCM. Here, we report a NGS strategy applied to pools of 8 DNAs from DCM patients and validate its robustness for rare variants detection at 4-fold reduced cost. Our pipeline uses Freebayes to detect variants with the expected 1/16 allele frequency. From the whole set of detected rare variants in 96 pools we set the variants quality parameters optimizing true positives calling. When compared to simplex DNA sequencing in a shared subset of 50 DNAs, 96% of SNVs/InsDel were accurately identified in pools. Extended to the 384 DNAs included in the study, we detected 100 variants (ACMG class 4 and 5), mostly in well-known morbid gene causing DCM such as TTN, MYH7, FLNC, and TNNT2. To conclude, we report an original pool-sequencing NGS method accurately detecting rare variants. This innovative approach is cost-effective for genetic diagnostic in rare diseases.PMID:37904629 | DOI:10.1111/cge.14427
Source: Clinical Genetics - Category: Genetics & Stem Cells Authors: Claire Perret Carole Proust Ulrike Esslinger Flavie Ader Jan Haas Jean-Fran çois Pruny Richard Isnard Pascale Richard David-Alexandre Tr égouët Philippe Charron Fran çois Cambien Eric Villard Source Type: research
More News: Cardiology | Cardiomyopathy | Dilated Cardiomyopathy | Genetics | Heart | Heart Disease | Rare Diseases | Study